The High-Risk Leukemia/Lymphoma (HRLL) Fellowship Program at Seattle Children’s Hospital (SCH) provides multidisciplinary care for children with high-risk leukemias and lymphomas who require treatment plans beyond standard chemotherapy, including cellular immunotherapy and hematopoietic stem cell transplant (HCT). This program has a broad national referral base for novel experimental therapies for children with high-risk leukemias and lymphomas. SCH/Ben Towne Center for Childhood Cancer Research (BTCCR) and Fred Hutch Cancer Center are international leaders in disease biology and early phase biologically-driven pharma, immunotherapy and HCT trials for children with HRLL. The HRLL fellowship will provide broad multidisciplinary experience in the management of children and adolescents with HRLL and exposure to current best active therapies, including HCT, as well as early phase and novel trial therapies in oncology and HCT. |
About the Fellowship
Applications for the July 2026 start date are now closed; however, we are currently accepting applications for the July 2027 start date, with an application deadline of December 31, 2026.
Eligibility Criteria
- American Board of Pediatrics certified or eligible in Pediatrics
- American Board of Pediatrics certified or eligible in either Pediatric Hematology/Oncology/BMT in the United States or Canada upon matriculation
- Eligible to obtain a Washington state medical licensure
Application Requirements
- Application
- Curriculum vitae (CV)
- Personal statement
- Three letters of recommendation
- Color photograph